DT Chard and SA Trip evidence suggests that high doses of corticosteroids could be an independent protective factor against tissue destruction produced by new inflammatory lesions observed in MRI.
Given that in MS the immunological processes are thought to drive neuro-axonal loss, high doses of corticosteroid administration, due to the strong and unspecific anti-inflammatory effect, could have a positive impact on asymptomatic MRI lesion evolution. Thus, high doses of corticosteroids could have beneficial implications in clinical practice, since it is possible to hypothesize that the treatment of patients with new T2 or CELs could reduce the probability of CNS tissue loss by counteracting the detrimental effect of CNS inflammation. 7 Based on the aforementioned research, an asymptomatic new lesion on MRI should be considered as a relapse and treated accordingly. However, further studies on larger cohorts are required to confirm the effectiveness of this intervention in clinical practice.
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The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. 3 a new lesion seen using MRI is now considered essentially equivalent to a relapse when making a diagnosis of RRMS. 1 However, while MRI evidence can substantially decrease the time needed to make a diagnosis of MS, it does so at the expense of clinical specificity. 4 When considering MS disease-modifying treatments, MRI has played a very important role in drug development, and at a group level, a treatment effect on WM lesion accrual predicts the effect on relapses and does so in much smaller and shorter trials. 5 However, at the level of an individual with MS, we think that asymptomatic lesions seen on MRI should be regarded with greater caution. While mindful that the early use of higher potency agents reduces risk of, or at least delays onset of, secondary progressive MS, 6 even if we agree that the aim of MS disease-modifying treatment is to suppress all inflammatory activity (some have argued that early relapses play a relatively minor role in longer term disability progression), there are several reasons to consider MRI findings with care. The main issue is that lesion appearances on MRI are not pathologically specific; for example, vascular and MS lesions can look the same. Furthermore, normal ageing is associated with brain lesion accrual, and more are seen in people with cardiovascular risk factors or a history of migraine. As such, not all new brain lesions seen in a person with MS are necessarily due to MS. Lesion location may provide clues about aetiology (e.g. lesions occurring in non-watershed regions are more likely to be MS related), but this still does not offer certainty.
Beyond this, the work of Río and colleagues 7 suggests that defining treatment failure purely on MRI grounds may lead to treatment escalation without the prospect of clinical benefit. In their study in people with MS on beta interferon, they found the accrual of ⩽2 MRI visible lesions over a year, or the presence of a single gadolinium contrast enhancing lesion within a year, was not associated with a greater risk of increasing disability over the next ~7 years. They did not assess lesion location, but we think that this should also be considered when guiding people with MS in their treatment choices, as lesions are not necessarily prognostically equal. For example, lesions in the posterior fossa, when compared with elsewhere in the brain, appear to be associated with more disabling outcomes. 8 This said, symptoms are a far from an ideal marker of MS inflammatory activity. Tallantyre and colleagues 9 found that symptoms leading a patient to attend an MS relapse clinic were ultimately not thought to be due to an MS relapse in ~40% of cases. Where there is doubt about the source of symptoms, MRI can be used to look for a potentially causative lesion, but the absence of a lesion does not mean that an episode of symptoms is unrelated to inflammation: about 30% to 40% of WM, and nearly all grey matter, MS lesions will be overlooked on conventional MRI scans. 10 Given this, we argue that even with an absolute approach to suppressing inflammation, a nuanced weighing of clinical and radiological evidence is needed.
In conclusion, we do not think that asymptomatic MRI-detected lesions can be regarded as equivalent to a relapse. Instead, they should be considered alongside rather than as a substitute for clinical findings, with the rate of accrual and location of lesions, and co-morbidities, also taken into account. Furthermore, we believe that the prognostic value of clinical and MRI evidence should be balanced against a frank assessment of the risks and benefits of each treatment. A mechanical approach, where any new lesion seen on MRI leads to treatment initiation or escalation, may result in more harm than good and for a person with MS may exhaust their treatment options unnecessarily.
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